In-depth research on UK equities, sectors and market structure from the Openbook team. Each article carries its own byline.
Final Hold rating on easyJet. Capex timing is the swing factor. Upside if capex normalises early and holidays scales; downside if fuel and capacity stay elevated. Part 5 of a 5-part series.
Read full noteeasyJet DCF — five-year forecast, 12% revenue CAGR, 12% WACC, 2% terminal growth. Implied share price of 90p versus 470p market price. Part 4 of a 5-part series.
Revenue growth is improving but it's volume-led, not pricing-led. Costs are mostly outside management's control. ROCE has rebuilt to 18%. Part 3 of a 5-part series.
European travel demand remains supportive for easyJet, but Ryanair leads on scale and Wizz Air keeps the pressure on price. Part 2 of a 5-part easyJet series.
easyJet has recovered from the pandemic, but the investment case still hinges on free cash flow during a heavy fleet investment cycle. Part 1 of a 5-part series.
Our Top Stocks portfolio is up 17.5% over the first five months of the year against 4.3% for the FTSE All-Share — roughly four times the index. An honest breakdown of what drove it, including how much rode on just three names.
The FTSE 250's 30-40% discount to global peers reflects a market that has stopped believing in rate cuts. The pivot, when it comes, will be sharpest in real estate, utilities and selected consumer names.
The FTSE 100's value-and-income reputation hides a substantial cohort of compounders. We profile five of them — what drives the growth, what the consensus debate is, and what the risks look like.
Lloyds trades close to tangible book value and yields over 5%. The relative cheapness is real. So is the FCA motor finance investigation that explains it.
Rolls-Royce has risen more than 400% from its 2022 low. The debate now is whether the civil aerospace flying hour trajectory and the SMR optionality can carry a multiple that prices both.
A 9% yield on a FTSE 100 stock is either a generational income opportunity or a warning the market is pricing a dividend cut. The difference matters. We profile five of the index's top yielders.
AZN is the FTSE 100's largest company and one of its most expensive. The investment case rests on whether the late-stage oncology pipeline can replace Tagrisso revenue before biosimilar competition arrives at the end of the decade.
Hyperscaler PPAs with Vistra, TerraPower and Oklo signal that AI demand is now a primary driver of nuclear capacity decisions. The investable winners are not the technology developers.
Software multiples have compressed on disruption fears. The pick-and-shovel beneficiaries of the AI build-out — utilities, regulated infrastructure, waste — have not. We see the gap as the cleanest defensive play of 2026.
Modular nuclear is the cleanest fit for the AI power story on paper. In practice, three commercial projects have already been cancelled or scaled back. Our view on the survivors.
The decision to back Rolls-Royce over Westinghouse was a sovereign supply-chain choice as much as an engineering one. The investment case rests on whether the export pipeline converts.